Scholarlink

<p>Epicardial adipose tissue (EAT) is an emerging cardiometabolic risk factor in type 2 diabetes mellitus (T2DM). While SGLT-2 inhibitors (SGLT-2i) offer cardiovascular benefits, their specific effects on EAT and left ventricular (LV) remodeling and function in Asian populations remain understudied. This study investigated the relationship between SGLT-2i on cardiometabolic parameters, EAT thickness and LV function in Malaysian patients with T2DM and coronary artery disease (CAD). A total of 360 patients with T2DM and CAD were divided into non-SGLT-2i and SGLT-2i groups. Anthropometric, cardiometabolic, and echocardiographic measurements were analyzed at baseline and post-6 months for 302 patients who competed the study (<i>n</i> = 151 per group). Both groups showed improvements in glycemic control (fasting blood glucose − 1.7 vs. − 2.6 mmol/L; HbA1c − 0.3% vs. − 0.6%; all <i>p</i> &lt; 0.001). Broader cardiometabolic benefits were observed predominantly among SGLT-2i group, including greater reductions in body mass index (– 0.7 vs. − 0.3&#xa0;kg/m<sup>2</sup>) and serum lipid concentrations (all <i>p</i> &lt; 0.001), a marked decrease in EAT thickness (–1 .5&#xa0;mm vs. + 0.6&#xa0;mm, <i>p</i> &lt; 0.001), and concomitant improvements in left ventricular structure, with reductions in LV mass (– 20 vs. + 7.8&#xa0;g) and increased LV ejection fraction (+ 4.6% vs. − 1.0%) (all <i>p</i> ≤ 0.01). Within the SGLT-2i group, EAT reduction was associated with lower body weight and BMI (<i>p</i> &lt; 0.05) but was independent of glycemic changes. Reductions in body weight and BMI were associated with improvements in LV diameter and mass (<i>p</i> &lt; 0.05) and although not directly mediated by changes in EAT. Beyond glycemic control, SGLT-2i was associated with reduced EAT thickness and improved LV remodeling and function in Malaysian T2DM patients with CAD. The reduction in EAT thickness specifically was associated with lower body weight and BMI. These findings provide Asian population–specific evidence with distinct cardiometabolic and adiposity traits.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiometabolic associations of SGLT-2 inhibitors on epicardial adiposity and left ventricular function in type 2 diabetes mellitus with coronary artery disease: insights from Malaysian EpiCAD study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Wan Ahmad Syazani Mohamed,
  • Hasniza Zaman Huri,
  • Ahmad Syadi Mahmood Zuhdi,
  • Samshol Sukahri,
  • Khairul Nisa’ Ishak,
  • Mohd Nasiruddin Mansor,
  • Han Yin Lim,
  • Nurakmal Baharum,
  • Azrul Fahmi Jaharudin,
  • Nur Ain Zahidah Zainudin,
  • Aswir Abd Rashed,
  • Norizan Rosli,
  • Mohd Fairulnizal Md Noh,
  • Amira Hajirah Abd Jamil

摘要

Epicardial adipose tissue (EAT) is an emerging cardiometabolic risk factor in type 2 diabetes mellitus (T2DM). While SGLT-2 inhibitors (SGLT-2i) offer cardiovascular benefits, their specific effects on EAT and left ventricular (LV) remodeling and function in Asian populations remain understudied. This study investigated the relationship between SGLT-2i on cardiometabolic parameters, EAT thickness and LV function in Malaysian patients with T2DM and coronary artery disease (CAD). A total of 360 patients with T2DM and CAD were divided into non-SGLT-2i and SGLT-2i groups. Anthropometric, cardiometabolic, and echocardiographic measurements were analyzed at baseline and post-6 months for 302 patients who competed the study (n = 151 per group). Both groups showed improvements in glycemic control (fasting blood glucose − 1.7 vs. − 2.6 mmol/L; HbA1c − 0.3% vs. − 0.6%; all p < 0.001). Broader cardiometabolic benefits were observed predominantly among SGLT-2i group, including greater reductions in body mass index (– 0.7 vs. − 0.3 kg/m2) and serum lipid concentrations (all p < 0.001), a marked decrease in EAT thickness (–1 .5 mm vs. + 0.6 mm, p < 0.001), and concomitant improvements in left ventricular structure, with reductions in LV mass (– 20 vs. + 7.8 g) and increased LV ejection fraction (+ 4.6% vs. − 1.0%) (all p ≤ 0.01). Within the SGLT-2i group, EAT reduction was associated with lower body weight and BMI (p < 0.05) but was independent of glycemic changes. Reductions in body weight and BMI were associated with improvements in LV diameter and mass (p < 0.05) and although not directly mediated by changes in EAT. Beyond glycemic control, SGLT-2i was associated with reduced EAT thickness and improved LV remodeling and function in Malaysian T2DM patients with CAD. The reduction in EAT thickness specifically was associated with lower body weight and BMI. These findings provide Asian population–specific evidence with distinct cardiometabolic and adiposity traits.